Compare Stocks: TNFA, FOXX, EBON, and QCLS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EBON Ebang International	$2.00 -1.5%	$2.10	$1.61 ▼ $5.90	$13.28M	3	5,495 shs	3,182 shs
FOXX Foxx Development	$2.51 -2.3%	$2.96	$1.71 ▼ $7.90	$18.12M	-0.35	6,913 shs	2,281 shs
QCLS Mymd Pharmaceuticals	$2.81 +1.4%	$3.42	$2.50 ▼ $10.28	$11.54M	2.16	150,516 shs	158,323 shs
TNFA TNF Pharmaceuticals	$2.77 -3.1%	$3.44	$0.04 ▼ $8.94	$5.12M	2.04	32.22 million shs	113,825 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EBON Ebang International	0.00%	+4.56%	-0.59%	-3.17%	-49.68%
FOXX Foxx Development	0.00%	-1.19%	-5.86%	-44.01%	-59.84%
QCLS Mymd Pharmaceuticals	0.00%	-5.14%	-19.48%	-28.79%	+276,999,900.00%
TNFA TNF Pharmaceuticals	0.00%	-5.14%	-16.06%	-36.03%	-72.57%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EBON Ebang International	$2.00 -1.5%	$2.10	$1.61 ▼ $5.90	$13.28M	3	5,495 shs	3,182 shs
FOXX Foxx Development	$2.51 -2.3%	$2.96	$1.71 ▼ $7.90	$18.12M	-0.35	6,913 shs	2,281 shs
QCLS Mymd Pharmaceuticals	$2.81 +1.4%	$3.42	$2.50 ▼ $10.28	$11.54M	2.16	150,516 shs	158,323 shs
TNFA TNF Pharmaceuticals	$2.77 -3.1%	$3.44	$0.04 ▼ $8.94	$5.12M	2.04	32.22 million shs	113,825 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EBON Ebang International	0.00%	+4.56%	-0.59%	-3.17%	-49.68%
FOXX Foxx Development	0.00%	-1.19%	-5.86%	-44.01%	-59.84%
QCLS Mymd Pharmaceuticals	0.00%	-5.14%	-19.48%	-28.79%	+276,999,900.00%
TNFA TNF Pharmaceuticals	0.00%	-5.14%	-16.06%	-36.03%	-72.57%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EBON Ebang International	1.00	Sell	N/A	N/A
FOXX Foxx Development	1.00	Sell	N/A	N/A
QCLS Mymd Pharmaceuticals	1.00	Sell	N/A	N/A
TNFA TNF Pharmaceuticals	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest TNFA, FOXX, EBON, and QCLS Analyst Ratings

Date	Company	Brokerage	Action	Rating
8/11/2026	FOXX Foxx Development	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/7/2026	QCLS Mymd Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/28/2026	FOXX Foxx Development	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/13/2026	EBON Ebang International	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/7/2026	FOXX Foxx Development	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/26/2026	EBON Ebang International	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/18/2026	FOXX Foxx Development	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/2/2026	FOXX Foxx Development	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 8/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EBON Ebang International	$6.54M	2.00	N/A	N/A	$37.44 per share	0.05
FOXX Foxx Development	$65.92M	0.27	N/A	N/A	($0.79) per share	-3.18
QCLS Mymd Pharmaceuticals	N/A	N/A	N/A	N/A	$5.19 per share	N/A
TNFA TNF Pharmaceuticals	N/A	N/A	N/A	N/A	$286.76 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EBON Ebang International	-$14.09M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FOXX Foxx Development	-$9.02M	-$6.87	N/A	N/A	N/A	-79.80%	N/A	-59.35%	N/A
QCLS Mymd Pharmaceuticals	-$11.63M	-$20.69	N/A	N/A	N/A	N/A	-91.64%	-47.48%	N/A
TNFA TNF Pharmaceuticals	-$23.36M	-$231.00	N/A	N/A	N/A	N/A	-69.21%	-33.98%	N/A

Latest TNFA, FOXX, EBON, and QCLS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	EBON Ebang International	N/A	-$0.23	N/A	-$0.23	N/A	$1.96 million
8/12/2026	Q2 2026	QCLS Mymd Pharmaceuticals	N/A	-$0.79	N/A	-$0.79	N/A	N/A
5/20/2026	Q3 2026	FOXX Foxx Development	N/A	-$5.19	N/A	-$5.19	N/A	$8.67 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
EBON Ebang International	N/A	N/A	N/A	N/A	N/A
FOXX Foxx Development	N/A	N/A	N/A	N/A	N/A
QCLS Mymd Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TNFA TNF Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EBON Ebang International	N/A	27.31	26.85
FOXX Foxx Development	N/A	0.38	0.20
QCLS Mymd Pharmaceuticals	N/A	3.29	3.29
TNFA TNF Pharmaceuticals	N/A	0.93	0.93

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EBON Ebang International	1.15%
FOXX Foxx Development	60.44%
QCLS Mymd Pharmaceuticals	9.64%
TNFA TNF Pharmaceuticals	9.64%

Insider Ownership

Company	Insider Ownership
EBON Ebang International	25.40%
FOXX Foxx Development	31.60%
QCLS Mymd Pharmaceuticals	0.86%
TNFA TNF Pharmaceuticals	0.45%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EBON Ebang International	260	6.54 million	4.88 million	No Data
FOXX Foxx Development	N/A	7.04 million	4.82 million	N/A
QCLS Mymd Pharmaceuticals	6	4.17 million	4.13 million	N/A
TNFA TNF Pharmaceuticals	6	1.85 million	1.84 million	N/A

TNFA, FOXX, EBON, and QCLS Headlines

Recent News About These Companies

TNF Pharmaceuticals (Formerly MyMD Pharmaceuticals) Begins Trading Under New Nasdaq Stock Symbol “TNFA” Effective Before Market Open Today

June 23, 2026 | businesswire.com

Tnf Pharmaceuticals: A Corporate Pivot Under Scrutiny

February 24, 2026 | newscase.comN

Why did QCLS stock surge over 60% today?

December 4, 2025 | msn.com

Rheumatoid Arthritis Market to Surge by 2034 as Next-Generation Biologics and JAK Inhibitors Gain Traction | DelveInsight

November 5, 2025 | finance.yahoo.com

Forward Therapeutics Announces First Participants Dosed in Phase 1 Healthy Volunteer Study of FT2109, a Next-Generation TNF Signaling Inhibitor

October 30, 2025 | markets.businessinsider.com

Q/C Technologies (Formerly TNF Pharmaceuticals) Commences Trading on Nasdaq Under New Ticker Symbol "QCLS"

September 26, 2025 | tmcnet.com

TNF Pharmaceuticals changes name to Q/C Technologies

September 25, 2025 | msn.com

TNF Pharmaceuticals stock soars after strategic pivot to quantum computing

September 25, 2025 | investing.com

TNF Pharmaceuticals regains compliance with Nasdaq

September 17, 2025 | msn.com

TNF Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

September 17, 2025 | businesswire.com

TNF Pharmaceuticals Announces Closing of $7 Million Private Placement

September 4, 2025 | businesswire.com

TNF Pharmaceuticals stock climbs after securing exclusive crypto computing rights

September 2, 2025 | investing.com

PharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency Applications

September 2, 2025 | businesswire.com

TNF Pharmaceuticals Announces Reverse Stock Split For Nasdaq Listing Compliance

August 29, 2025 | finance.yahoo.com

TNF Pharmaceuticals announces improved financial position

August 20, 2025 | msn.com

TNF Pharmaceuticals Strengthens Financial Position for Growth and Value Creation

August 19, 2025 | businesswire.com

TNF Pharmaceuticals Inc Ordinary Shares TNFA - Morningstar

July 11, 2025 | morningstar.comM

Akers files written objection to her Judicial Investigative admonishment

July 4, 2025 | wvgazettemail.comW

Dorothy Marillyn Akers

July 2, 2025 | chattanoogan.comC

Newly-signed running back Cam Akers has already changed his jersey number

June 30, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNFA, FOXX, EBON, and QCLS Company Descriptions

Ebang International NASDAQ:EBON

$2.00 -0.03 (-1.48%)

As of 01:32 PM Eastern

Ebang International Holdings Inc., through its subsidiaries, engages in the research, design, and development of application-specific integrated circuit chips and manufacture of Bitcoin mining machines under the Ebit brand in Singapore, Hong Kong, Australia, the Bahamas, and internationally. It also provides mining machine hosting services; and engages in the development of proprietary cryptocurrency exchange platform. In addition, the company offers fiber-optic communication access devices, including multiprotocol label switching fiber-optic access network devices, multi-service access platform integrated business access devices, and wavelength-division multiplexing fiber-optic devices; and enterprise convergent terminal products, which consists gigabit passive optical network, Fiber to the Room products, passive optical network converged gateways, enterprise cloud gateway devices, industrial Internet of Things access devices, and business enterprise smart wireless access devices. It serves the blockchain and telecommunications industries. The company also operates a cross-border payment and foreign exchange platform. It sells its blockchain products directly, as well as through its website; and telecommunication products under the EBANG brand name primarily through supplier contracts. The company was incorporated in 2018 and is headquartered in Hangzhou, China.

Foxx Development NASDAQ:FOXX

$2.51 -0.06 (-2.33%)

As of 04:00 PM Eastern

Foxx Development Holdings Inc. is a consumer electronics and integrated Internet-of-Things solution company catering to both retail and institutional clients. The company currently sells a diverse range of products including mobile phones, tablets and other consumer electronics devices principally in United State and is in the process of developing and distributing end-to-end communication terminals and IoT solutions. Foxx Development Holdings Inc., formerly known as Acri Capital Acquisition Corporation, is based in Austin, TX.

Mymd Pharmaceuticals NASDAQ:QCLS

$2.81 +0.04 (+1.44%)

As of 04:00 PM Eastern

TNF Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to treat diseases and disorders marked by acute or chronic inflammation. The company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.

TNF Pharmaceuticals NASDAQ:TNFA

$2.77 -0.09 (-3.15%)

As of 08/14/2026

TNF Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TNFA, FOXX, EBON, and QCLS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TNFA, FOXX, EBON, and QCLS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TNFA, FOXX, EBON, and QCLS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNFA, FOXX, EBON, and QCLS Company Descriptions

Ebang International NASDAQ:EBON

Foxx Development NASDAQ:FOXX

Mymd Pharmaceuticals NASDAQ:QCLS

TNF Pharmaceuticals NASDAQ:TNFA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TNFA, FOXX, EBON, and QCLS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TNFA, FOXX, EBON, and QCLS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TNFA, FOXX, EBON, and QCLS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNFA, FOXX, EBON, and QCLS Company Descriptions

Ebang International NASDAQ:EBON

Foxx Development NASDAQ:FOXX

Mymd Pharmaceuticals NASDAQ:QCLS

TNF Pharmaceuticals NASDAQ:TNFA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools